NEW YORK, January 25, 2018 /PRNewswire/ --
According to a report by Forbes, Brightfield Group indicates that the international market for cannabis is projected to hit $31.4 billion by 2021. The global market is estimated to see a compound annual growth rate of 60 percent as other countries relax their cannabis regulations. The U.S. currently drives 90 percent of global cannabis sales, but its share will drop to 57 percent by 2021. That's in large part thanks to Canada's plans to legalize recreational cannabis by July 2018. California has already legalized recreational products, the sales of which have started earlier this month. Global Payout, Inc. (OTC: GOHE), GB Sciences, Inc. (OTC: GBLX), United Cannabis Corporation (OTC: CNAB), American Cannabis Company, Inc. (QTC: AMMJ), CV Sciences, Inc. (OTC: CVSI)
Tom Adams, Editor-in-Chief at Arcview Market Research and Principal Analyst at BDS Analytics explained, "Our data shows positive indicators across the board for the legal cannabis industry, in North America and around the globe... The passage of the 2016 ballot initiatives and continued maturation of the existing Adult-Use markets are the primary drivers of the growth this year. That's nothing compared to what we can expect in 2018 and beyond from Nevada's tourism, and California and Canada planning to launch Adult-Use sales in 2018."
Global Payout, Inc. (OTC: GOHE) yesterday the company announced breaking news that, "its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company"), has executed a Letter of Intent ("LOI") with Eyeconic.tv, an innovative and award winning producer and distributor of interactive digital mediums aimed primarily at providing digital menus, advertising and kiosks to its customers within their businesses.
The execution of the LOI will provide the companies an opportunity to thoroughly explore the possibility of establishing a strategic partnership. MTRAC would look to integrate Eyeconic's digital media platform into the service offerings they continue to develop and enhance for businesses within the cannabis industry. More specifically, MTRAC will look to leverage the vast network of dispensaries and industry specific brands and products it has established through its PotSaver publication to bolster the sales and marketing efforts of Eyeconic's digital media platform throughout the rapidly expanding industry of retail cannabis.
Said MTRAC CEO, Vanessa Luna: "We are very excited to explore the possibility of establishing an official partnership with Eyeconic.TV that would be mutually beneficial to both of our companies in terms of creating new revenue streams as well as becoming a contributing factor to the growth of both of our companies in the cannabis industry. The digital media platform Eyeconic has developed is an impressive and truly valuable advertising and marketing tool for dispensaries and other products and brands throughout our industry, and I believe it is something we can successfully incorporate into our expanding suite of valuable sales and marketing services, in addition to utilizing it to support the continued growth of our PotSaver publication."
The companies intend to dedicate the next several days to completing the necessary due diligence, as well as exploring and analyzing the different angles that would be involved with the establishment of an official sales and marketing partnership. The Company will provide additional information and details as they become available."
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. On December 8, 2018, the company announced it currently markets both medical and adult use cannabis products in Nevada under the respected Cultivation Labs brand. By maximizing the production of critical raw materials that can only be derived from the cannabis plant, GB Sciences is able to provide the base materials for their proprietary cannabis-based medical formulations. This breakthrough places cannabis-based medical formulations on a level playing field with traditional medical formulations when it comes to patient studies and clinical trials; a task that, until now, has proven extremely difficult industry-wide. United Cannabis Corporation (OTCQB: CNAB) is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. On December 27, 2017, the company announced that it has secured an industrial building in Colorado where the Company will construct a state-of-the-art industrial hemp processing plant to provide contract manufacturing to farmers working under the 2014 Federal Farm Bill and Colorado's Department of Agriculture's Industrial Hemp Program. The multi-function Facility will include extraction, purification, testing and processing equipment, as well as packaging, fulfillment, and secure storage capabilities. American Cannabis Company, Inc. (QTCQB: AMMJ) offers end-to-end solutions to existing and aspiring participants in the cannabis industry. On January 17, 2018, the company announced that it has secured a consulting contract with Cloud 9 Apothecary in the state of California. In conjunction with the consulting agreement, ACC will acquire an equity stake in Cloud 9's project that is currently non-operational and in the development stage. This project, to be built-out and completed in Desert Springs, California, will comprise a closed-loop greenhouse containing a 22,000 square foot canopy of premium cannabis cultivars. With the construction of this facility, Cloud 9 Apothecary's plans focus on wholesale cultivation and product manufacturing. Plans to shift into a fully integrated business model, complete with dispensing solutions, will be made in the near future as Cloud 9 plans to scale up operations organically. CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. On November 14, 2017, the company announced it has been named on Deloitte's Technology Fast 500™, an annual ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy tech sectors in North America. 2017 marks CV Sciences' first year named on the Deloitte's Technology Fast 500™ list. Overall, 2017 Technology Fast 500™ companies achieved revenue growth ranging from 135% to 59,093% from 2013 to 2016, with median growth of 380%.
Subscribe Now! Watch us report from LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For global payout, inc. financial news dissemination and PR services, FinancialBuzz.com has been compensated four thousand dollars for financial news dissemination and PR services by cambridge consultants. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com
For further information: [email protected] +1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
Advertisement
According to a report by Forbes, Brightfield Group indicates that the international market for cannabis is projected to hit $31.4 billion by 2021. The global market is estimated to see a compound annual growth rate of 60 percent as other countries relax their cannabis regulations. The U.S. currently drives 90 percent of global cannabis sales, but its share will drop to 57 percent by 2021. That's in large part thanks to Canada's plans to legalize recreational cannabis by July 2018. California has already legalized recreational products, the sales of which have started earlier this month. Global Payout, Inc. (OTC: GOHE), GB Sciences, Inc. (OTC: GBLX), United Cannabis Corporation (OTC: CNAB), American Cannabis Company, Inc. (QTC: AMMJ), CV Sciences, Inc. (OTC: CVSI)
Advertisement
Tom Adams, Editor-in-Chief at Arcview Market Research and Principal Analyst at BDS Analytics explained, "Our data shows positive indicators across the board for the legal cannabis industry, in North America and around the globe... The passage of the 2016 ballot initiatives and continued maturation of the existing Adult-Use markets are the primary drivers of the growth this year. That's nothing compared to what we can expect in 2018 and beyond from Nevada's tourism, and California and Canada planning to launch Adult-Use sales in 2018."
Global Payout, Inc. (OTC: GOHE) yesterday the company announced breaking news that, "its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC", the "Company"), has executed a Letter of Intent ("LOI") with Eyeconic.tv, an innovative and award winning producer and distributor of interactive digital mediums aimed primarily at providing digital menus, advertising and kiosks to its customers within their businesses.
The execution of the LOI will provide the companies an opportunity to thoroughly explore the possibility of establishing a strategic partnership. MTRAC would look to integrate Eyeconic's digital media platform into the service offerings they continue to develop and enhance for businesses within the cannabis industry. More specifically, MTRAC will look to leverage the vast network of dispensaries and industry specific brands and products it has established through its PotSaver publication to bolster the sales and marketing efforts of Eyeconic's digital media platform throughout the rapidly expanding industry of retail cannabis.
Said MTRAC CEO, Vanessa Luna: "We are very excited to explore the possibility of establishing an official partnership with Eyeconic.TV that would be mutually beneficial to both of our companies in terms of creating new revenue streams as well as becoming a contributing factor to the growth of both of our companies in the cannabis industry. The digital media platform Eyeconic has developed is an impressive and truly valuable advertising and marketing tool for dispensaries and other products and brands throughout our industry, and I believe it is something we can successfully incorporate into our expanding suite of valuable sales and marketing services, in addition to utilizing it to support the continued growth of our PotSaver publication."
The companies intend to dedicate the next several days to completing the necessary due diligence, as well as exploring and analyzing the different angles that would be involved with the establishment of an official sales and marketing partnership. The Company will provide additional information and details as they become available."
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. On December 8, 2018, the company announced it currently markets both medical and adult use cannabis products in Nevada under the respected Cultivation Labs brand. By maximizing the production of critical raw materials that can only be derived from the cannabis plant, GB Sciences is able to provide the base materials for their proprietary cannabis-based medical formulations. This breakthrough places cannabis-based medical formulations on a level playing field with traditional medical formulations when it comes to patient studies and clinical trials; a task that, until now, has proven extremely difficult industry-wide. United Cannabis Corporation (OTCQB: CNAB) is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial markets. The Company has long advocated the application of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. On December 27, 2017, the company announced that it has secured an industrial building in Colorado where the Company will construct a state-of-the-art industrial hemp processing plant to provide contract manufacturing to farmers working under the 2014 Federal Farm Bill and Colorado's Department of Agriculture's Industrial Hemp Program. The multi-function Facility will include extraction, purification, testing and processing equipment, as well as packaging, fulfillment, and secure storage capabilities. American Cannabis Company, Inc. (QTCQB: AMMJ) offers end-to-end solutions to existing and aspiring participants in the cannabis industry. On January 17, 2018, the company announced that it has secured a consulting contract with Cloud 9 Apothecary in the state of California. In conjunction with the consulting agreement, ACC will acquire an equity stake in Cloud 9's project that is currently non-operational and in the development stage. This project, to be built-out and completed in Desert Springs, California, will comprise a closed-loop greenhouse containing a 22,000 square foot canopy of premium cannabis cultivars. With the construction of this facility, Cloud 9 Apothecary's plans focus on wholesale cultivation and product manufacturing. Plans to shift into a fully integrated business model, complete with dispensing solutions, will be made in the near future as Cloud 9 plans to scale up operations organically. CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. On November 14, 2017, the company announced it has been named on Deloitte's Technology Fast 500™, an annual ranking of the fastest growing companies in the technology, media, telecommunications, life sciences and energy tech sectors in North America. 2017 marks CV Sciences' first year named on the Deloitte's Technology Fast 500™ list. Overall, 2017 Technology Fast 500™ companies achieved revenue growth ranging from 135% to 59,093% from 2013 to 2016, with median growth of 380%.
Subscribe Now! Watch us report from LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For global payout, inc. financial news dissemination and PR services, FinancialBuzz.com has been compensated four thousand dollars for financial news dissemination and PR services by cambridge consultants. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com
For further information: [email protected] +1-877-601-1879
Url: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com
